Bayer, J&J kick off 2 more trials of rivaroxaban

03/12/2013 | PharmaTimes (U.K.)

Bayer and Johnson & Johnson are initiating two late-stage trials of the anticoagulant rivaroxaban after failing to get expanded FDA approval for the prevention of cardiovascular events in patients with acute coronary syndrome. One trial will involve individuals with chronic heart failure and significant coronary artery disease. The other will include patients with nonvalvular atrial fibrillation.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC